Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as an injectable solution for intravenous infusion. It provides passive immunity and is used to treat primary and secondary immunodeficiency diseases, immune thrombocytopenic purpura, and Kawasaki disease in appropriate patients.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to global quality standards and provides cold‑chain logistics for biologic products, ensuring product integrity from manufacturing to delivery.

Intratect is an intravenous immunoglobulin used to replace deficient antibodies in various immune‑mediated conditions.

- Primary immunodeficiency diseases: restores normal IgG levels to reduce infection risk. - Secondary immunodeficiency (e.g., post‑bone marrow transplantation): provides passive immunity while the patient’s immune system recovers. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications in acute cases.

Intratect may be associated with infusion‑related reactions and, rarely, severe systemic events.

Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever and chills: transient rise in temperature with shaking sensations. - Nausea or vomiting: gastrointestinal discomfort that usually resolves with supportive care. - Fatigue: feeling of tiredness that improves after the infusion period.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: blood clots that can affect veins or arteries. - Acute renal failure: sudden loss of kidney function, particularly in high‑dose or rapid infusions. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia.

Before initiating Intratect therapy, clinicians should evaluate patient risk factors and implement monitoring strategies.

- Assess renal function: monitor serum creatinine and urine output before and during treatment. - Screen for IgA deficiency: avoid use in patients with anti‑IgA antibodies to reduce anaphylaxis risk. - Monitor for thrombotic risk: consider prophylactic anticoagulation in patients with known clotting disorders. - Observe infusion rate: start at a slow rate and adjust based on patient tolerance and adverse reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other therapies, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection; avoid concurrent administration. - High‑dose immunosuppressants (e.g., rituximab): can diminish the therapeutic benefit of IVIG. - Nephrotoxic agents (e.g., aminoglycosides): increase risk of renal impairment when combined.

Moderate Interactions (Monitor Closely): - Inactivated vaccines: may have reduced immunogenic response; assess antibody titers. - Diuretics: may affect fluid balance; monitor electrolytes and volume status. - ACE inhibitors or ARBs: watch for blood pressure changes during infusion.